Liquid Biopsy in Colorectal Cancer: Quo Vadis? Implementation of Liquid Biopsies in Routine Clinical Patient Care in Two German Comprehensive Cancer Centers.
CGP
CRC
clinical practice
ctDNA
liquid biopsy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
06
02
2022
accepted:
11
04
2022
entrez:
1
6
2022
pubmed:
2
6
2022
medline:
2
6
2022
Statut:
epublish
Résumé
The use of liquid biopsies (LB) in patients with solid malignancies enables comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) and has the potential to guide therapy stratification and support disease monitoring. To examine clinical uptake of LB in a real-world setting, LB implementation was analyzed at two German cancer centers (LMU Munich and Charité - Universitätsmedizin Berlin) between 2017 and 2021, with focus on colorectal cancer (CRC) patients. In this retrospective analysis, all patients who received a LB between January 2017 and December 2021 as part of routine clinical management were included. To provide adequate context, we collected disease characteristics and technical specifications of the LB methods applied. Additionally, we examined the concordance of In total, our cohort included 86 CRC patients and 161 LB conducted in these patients between 2017 and 2021. In 59 patients, comparison between tissue-based and liquid-based molecular diagnostics, revealed a divergence in 23 (39%) of the evaluable samples. Our real-world data analysis indicates that the possibilities of LB are not yet exploited in everyday clinical practice. Currently, the variety of methods and lack of standardization, as well as restricted reimbursement for liquid based CGP hinder the use of LB in clinical routine. To overcome these issues, prospective clinical trials are needed to provide evidence driving the implementation of LB into the management of CRC patients and to support their implementation into clinical guidelines.
Identifiants
pubmed: 35646657
doi: 10.3389/fonc.2022.870411
pmc: PMC9134071
doi:
Types de publication
Journal Article
Langues
eng
Pagination
870411Informations de copyright
Copyright © 2022 Fischer, Stintzing, Heinemann, Keilholz, Keune, Vollbrecht, Burmeister, Kind, Weiss, Horst, Kirchner, Klauschen, Jung, Westphalen and Jelas.
Déclaration de conflit d'intérêts
Author TB was employed by Labor Berlin – Charité Vivantes GmbH. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Genome Med. 2020 Jan 14;12(1):8
pubmed: 31937368
Oncogene. 2021 Aug;40(33):5204-5212
pubmed: 34230613
J Clin Oncol. 2014 Feb 20;32(6):579-86
pubmed: 24449238
Nat Rev Clin Oncol. 2020 Dec;17(12):757-770
pubmed: 32632268
Nat Med. 2015 Jul;21(7):795-801
pubmed: 26030179
Front Oncol. 2021 Nov 18;11:763790
pubmed: 34868984
J Clin Oncol. 2018 Oct 30;:JCO2018789032
pubmed: 30376428
Br J Cancer. 2011 Jul 12;105(2):239-45
pubmed: 21712823
Nature. 2012 Jun 28;486(7404):532-6
pubmed: 22722830
JAMA Oncol. 2018 Apr 12;4(4):e175245
pubmed: 29423521
Ann Oncol. 2015 Apr;26(4):731-736
pubmed: 25628445
Curr Pathobiol Rep. 2018;6(4):275-286
pubmed: 30595972
Front Oncol. 2020 Jul 16;10:1115
pubmed: 32766143
J Clin Oncol. 2019 Jun 10;37(17):1460-1469
pubmed: 30892987
Eur J Cancer. 2021 Aug;153:86-95
pubmed: 34153718
Int J Cancer. 2020 Aug 15;147(4):1185-1189
pubmed: 31472013
Cancer Discov. 2016 Feb;6(2):147-153
pubmed: 26644315
Br J Cancer. 2018 Aug;119(4):419-423
pubmed: 30072744
Mol Aspects Med. 2020 Apr;72:100828
pubmed: 31711714
Ann Oncol. 2020 Nov;31(11):1491-1505
pubmed: 32853681
J Clin Oncol. 2018 Jun 1;36(16):1631-1641
pubmed: 29504847
Clin Cancer Res. 2017 Sep 15;23(18):5437-5445
pubmed: 28600478
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
CA Cancer J Clin. 2021 Mar;71(2):176-190
pubmed: 33165928
Br J Cancer. 2014 Oct 14;111(8):1482-9
pubmed: 25157833
Ann Oncol. 2018 Jan 1;29(1):119-126
pubmed: 28945848
Clin Chem. 2006 Jun;52(6):1062-9
pubmed: 16723681
Nat Rev Clin Oncol. 2021 May;18(5):297-312
pubmed: 33473219
Gut. 2016 Apr;65(4):625-34
pubmed: 25654990
JCO Precis Oncol. 2020 Nov;4:898-911
pubmed: 35050760
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
Nat Rev Clin Oncol. 2017 Sep;14(9):531-548
pubmed: 28252003
Nat Commun. 2021 Jan 4;12(1):11
pubmed: 33397889
JCO Precis Oncol. 2020 Sep 16;4:
pubmed: 33015528
Theranostics. 2020 Jan 1;10(2):856-866
pubmed: 31903155